At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Cetuximabdrug
Likely dose
Cetuximab 400mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Neoadjuvant Chemotherapy + IMRT Combined With Cetuximab in Advanced T Stage of Nasopharyngeal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Cetuximab for Nasopharyngeal Carcinoma. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal carcinoma. Besides, to figure out the relationship between patient outcome and EGFR gene copy number, expression and mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
CollaboratorsZhejiang Cancer Hospital, Wenzhou Medical University, First Affiliated Hospital of Guangxi Medical University, Xijing Hospital, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan University, Hubei Cancer Hospital, Tongji University, Affiliated Cancer Hospital of Shantou University Medical College, Shenzhen People's Hospital, First People's Hospital of Foshan
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedJan 2011
Primary CompletionJun 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJan 6, 2011
Enrollment StartSep 1, 2010
Primary CompletionJun 1, 2012
Study CompletionDec 1, 2012
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 15.5 years ago
Interventions
Cetuximabdrug
400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy